AGP Limited will soon sell COVID 19 treatment in Pakistan
According to Bloomberg, AGP Limited, a Pakistan-based pharmaceutical company, plans to sell COVID 19 treatments in the country in one to two months from now.
Remedyware is an antiviral drug that has reduced the duration of symptoms from 15 days to 11 days in clinical trials in hospitals around the world.
According to AGP CEO Nusrat Munshi, the pharmaceutical company will seek permission from the country's drug authority to import drugs from the Dutch pharmaceutical company Milan. There is a similar arrangement with Milan to import hepatitis C treatment. AGP Milan is a specialized distributor in Pakistan.
Also read: Treatment reduces recovery from coronary artery disease: study
Global pressure to treat and develop vaccines for the coronavirus is mounting as governments seek ways to end the recovery and resume financial activity to revive the economy.
The original creator of the Glade Sciences Inc. memo, based in Foster City, California, was originally developed in 2010 to treat Ebola, under contract with four major drug manufacturers in India, including Myelin. The unit is also included. This will help accelerate growth in Pakistan and meet the expected demand.
The Moderna Inc. vaccine passed a major safety test last week, and countries coming to China from the UK will have to develop their own vaccines.
ALSO READ: Remediation Business Talks with Pakistani and Indian Firms to Develop COVID 19 Medicine
To date, the AGP has also sold nearly 100,000 antibody polishing kits to hospitals and private staff for testing their staff as people have been evacuated by the government before Eid al-Fitr. Went back to work
The report highlights that, according to Munshi, the company still has 100,000 seats and is considering importing because it looks like high demand.
No comments:
Post a Comment